Leerink Swann reissued their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Wednesday. Leerink Swann currently has a $169.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, November 1st. TheStreet downgraded shares of Alexion Pharmaceuticals from a b- rating to a c+ rating in a research report on Friday, November 10th. Royal Bank Of Canada boosted their price target on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Piper Jaffray Companies restated an overweight rating and set a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Stifel Nicolaus dropped their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating on the stock in a research report on Tuesday, October 24th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of Buy and a consensus price target of $154.49.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) opened at $114.46 on Wednesday. The firm has a market cap of $25,571.51, a PE ratio of 23.41, a P/E/G ratio of 1.24 and a beta of 1.18. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same period last year, the firm posted $1.23 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. equities analysts predict that Alexion Pharmaceuticals will post 4.82 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI grew its stake in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after purchasing an additional 79,943 shares during the last quarter. HPM Partners LLC grew its stake in shares of Alexion Pharmaceuticals by 267.2% in the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 4,861 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Alexion Pharmaceuticals by 1.2% in the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after purchasing an additional 4,115 shares during the last quarter. 94.16% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals’ (ALXN) Buy Rating Reiterated at Leerink Swann” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/10/alexion-pharmaceuticals-alxn-buy-rating-reiterated-at-leerink-swann.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.